Hirahara Mitsuho, Nakajo Masatoyo, Kitazano Ikumi, Jinguji Megumi, Tani Atsushi, Takumi Koji, Kamimura Kiyohisa, Tanimoto Akihide, Yoshiura Takashi
Department of Radiology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan.
Mol Imaging Biol. 2024 Dec;26(6):1005-1015. doi: 10.1007/s11307-024-01952-8. Epub 2024 Sep 18.
To examine the usefulness of semi-quantitative analysis using the standardized uptake value (SUV) of iodine-123 metaiodobenzylguanidine ([I]-MIBG) for predicting metastatic potential in patients with pheochromocytoma (PHEO) and paraganglioma (PGL).
This study included 18 PHEO and 2 PGL patients. [I]-MIBG visibility and SUV-related parameters (SUVmax, SUVmean, tumor volume of [I]-MIBG uptake [TV_MIBG], and total lesion [I]-MIBG uptake) were compared with the pathological grading obtained using the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP), which are used to predict metastatic potential. The PASS scores were categorized as < 4 and ≥ 4. Based on the GAPP scores, PHEOs/PGLs were categorized as follows: well, moderately, and poorly differentiated tumors. The Mann-Whitney U test or Spearman's rank correlation was used to assess differences or associations between two quantitative variables.
All PHEOs/PGLs were visualized on [I]-MIBG scintigraphy. There were 16 PASS < 4 and 4 PASS ≥ 4 tumors. Moreover, 11 and 9 tumors were well and moderately differentiated, respectively. The uptake scores and SUV-related parameters significantly differed between tumors with a PASS score of < 4 and those with a PASS score of ≥ 4 (each, p > 0.05). Moderately differentiated tumors had significantly higher uptake scores and SUV-related parameters except TV_MIBG than well-differentiated tumors (each, p < 0.05). The GAPP score was positively correlated with the uptake scores and SUV-related parameters (each, p < 0.05) except TV_MIBG.
The primary tumor [I]-MIBG uptake assessed using SUV-related parameters can be an imaging tool for predicting metastatic potential in patients with PHEO/PGL.
探讨使用碘-123间碘苄胍([I]-MIBG)的标准化摄取值(SUV)进行半定量分析对预测嗜铬细胞瘤(PHEO)和副神经节瘤(PGL)患者转移潜能的有效性。
本研究纳入了18例PHEO患者和2例PGL患者。将[I]-MIBG的显影情况和SUV相关参数(SUVmax、SUVmean、[I]-MIBG摄取肿瘤体积[TV_MIBG]以及总病灶[I]-MIBG摄取量)与使用肾上腺嗜铬细胞瘤分级量表(PASS)和肾上腺嗜铬细胞瘤及副神经节瘤分级系统(GAPP)获得的病理分级进行比较,这两种分级系统用于预测转移潜能。PASS评分分为<4分和≥4分。根据GAPP评分,将PHEO/PGL分为以下几类:高分化、中分化和低分化肿瘤。采用Mann-Whitney U检验或Spearman等级相关分析评估两个定量变量之间的差异或关联。
所有PHEO/PGL在[I]-MIBG闪烁显像中均可见。有16个肿瘤的PASS<4分,4个肿瘤的PASS≥4分。此外,分别有11个和9个肿瘤为高分化和中分化。PASS评分<4分的肿瘤与PASS评分≥4分的肿瘤之间,摄取分数和SUV相关参数存在显著差异(均p>0.05)。中分化肿瘤的摄取分数和除TV_MIBG外的SUV相关参数显著高于高分化肿瘤(均p<0.05)。GAPP评分与摄取分数和除TV_MIBG外的SUV相关参数呈正相关(均p<0.05)。
使用SUV相关参数评估的原发性肿瘤[I]-MIBG摄取情况可作为预测PHEO/PGL患者转移潜能的一种影像学工具。